Breast Implant-Associated ALCL Diagnosis, Surgery & Specialist Access

BIA-ALCL (breast implant-associated anaplastic large cell lymphoma) is not a breast cancer. It is a lymphoma — a cancer of the immune system — that arises in the fluid and fibrous capsule surrounding textured breast implants, not from the breast glandular tissue itself. It is a type of T-cell lymphoma (specifically ALK-negative, CD30-positive) and is classified as a distinct entity in the WHO Classification of Tumours. Understanding this distinction is important because BIA-ALCL is managed very differently from breast cancer, primarily by surgical removal of the implant and its surrounding capsule rather than by breast cancer chemotherapy or hormone therapy.

BIA-ALCL is associated with textured breast implants — both saline-filled and silicone-filled — not with smooth implants. The rough surface of textured implants generates a chronic inflammatory environment around the implant capsule that is associated with the development of BIA-ALCL in susceptible individuals. The risk varies by degree of texturing: highly textured macro-surface implants (such as those manufactured by Allergan under the Biocell process, which were recalled by the FDA in 2019) carry substantially higher estimated risk than lower-texture implants. Smooth breast implants are associated with very few, if any, confirmed BIA-ALCL cases.

The primary warning sign of BIA-ALCL is a new, late-onset swelling or enlargement of one breast — typically appearing more than one year after implantation, and often many years later. This swelling is caused by fluid (seroma) accumulating around the implant. Other symptoms may include a palpable firm mass in or near the breast capsule, breast asymmetry, skin redness overlying the breast, or pain around the implant. Any patient with textured breast implants who develops unexplained new unilateral breast swelling — particularly if it develops gradually over weeks or months — should seek urgent specialist evaluation. Do not assume that delayed seroma is harmless; it requires CD30 testing of the fluid.

Total en bloc capsulectomy is the surgical procedure of removing the breast implant together with its entire surrounding fibrous capsule as a single uninterrupted specimen — without opening, cutting into, or perforating the capsule during removal. This technique is essential in BIA-ALCL because the tumour cells are present on and within the capsule lining; any violation of the capsule during surgery risks spilling lymphoma cells into the surrounding breast tissue, potentially upstaging the disease. Simple implant removal (without complete capsule excision), partial capsulectomy, or capsule perforation are inadequate surgical approaches and are associated with higher relapse risk. This procedure should be performed by a surgeon experienced specifically in BIA-ALCL surgical technique.

For the majority of patients — whose BIA-ALCL is diagnosed at a localised stage (confined to the seroma fluid and inner capsule surface) — total en bloc capsulectomy is curative in the great majority of cases. This is one of the most favourable outcomes in all lymphoma subtypes. A small proportion of patients present with more advanced disease involving regional lymph nodes or distant spread; these cases require systemic chemotherapy (brentuximab vedotin–containing regimens) and carry a less favourable but still potentially treatable prognosis. Early diagnosis through prompt investigation of peri-implant symptoms is the most important factor in ensuring a curative outcome.

This decision is individualised and should be made through a shared decision-making discussion with a specialist BIA-ALCL multidisciplinary team. The absolute risk of developing BIA-ALCL in the contralateral breast with a textured implant is low for most patients, but not zero. Factors informing the decision include the surface texture of the contralateral implant, the patient's preference regarding ongoing surveillance versus surgical removal, and the reconstructive options available. Many specialist centres offer prophylactic contralateral implant removal at the same operation as the diagnostic capsulectomy as a reasonable precaution, after thorough patient counselling.

Brentuximab vedotin (BV, Adcetris) is an antibody-drug conjugate that targets CD30 — a protein uniformly and strongly expressed on BIA-ALCL cells — and delivers a cell-killing payload directly to them. It is used in BIA-ALCL when the disease is advanced (Stage III–IV), when surgical resection cannot achieve clear margins, or when disease relapses after surgery. BV is combined with CHP chemotherapy (BV-CHP) as the standard systemic regimen for advanced BIA-ALCL. BV is not required for the majority of patients with localised Stage I–II disease who achieve R0 surgical resection.

Seroma fluid aspirated from around the implant is sent simultaneously for two analyses: CD30 flow cytometry (which detects the characteristic population of CD30-bright atypical T-cells that defines BIA-ALCL) and cytomorphological examination (which identifies the large, pleomorphic lymphoma cells under the microscope). A positive result — bright CD30 by flow cytometry in a population of large atypical lymphoid cells — is highly specific for BIA-ALCL when combined with the appropriate clinical context. A minimum of approximately 10 mL of fluid is needed for reliable analysis. The fluid must be transported promptly to a laboratory with flow cytometry expertise; this test is not available at all pathology laboratories.

Yes. CancerFax supports patients with BIA-ALCL by reviewing seroma cytology, capsule pathology, and staging imaging reports, coordinating second opinions at specialist centres with combined oncoplastic surgery and haematology/oncology expertise, assisting with access to brentuximab vedotin programmes for advanced disease, and facilitating connections with leading BIA-ALCL centres in India and internationally. Please share your medical reports through the CancerFax portal or contact our team to begin the process.